Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114829) titled 'Study on the Mechanism of SREBP/PCSK9 Pathway-Mediated Lipid Metabolism Abnormalities Induced by Olanzapine in Schizophrenia and the Therapeutic Effects of PCSK9 Inhibitors' on Dec. 17, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Shandong mental health center
Condition:
Olanzapine-induced lipid metabolism disorders
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2025-01-01
Target Sample Size: Olanzapine group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=276385
Published by HT Digital Co...